Stryker (NYSE:SYK) had its price objective boosted by BTIG Research to $219.00 in a report released on Monday, The Fly reports. The brokerage currently has a positive rating on the medical technology company’s stock.
A number of other research analysts have also recently commented on SYK. Svb Leerink reissued an outperform rating on shares of Stryker in a report on Wednesday, July 10th. Deutsche Bank increased their target price on shares of Texas Instruments from $100.00 to $110.00 and gave the stock a hold rating in a report on Wednesday, April 24th. Oppenheimer assumed coverage on shares of Kala Pharmaceuticals in a report on Wednesday, April 24th. They issued an outperform rating and a $11.00 target price for the company. ValuEngine raised shares of Yirendai from a strong sell rating to a sell rating in a report on Friday, May 3rd. Finally, Zacks Investment Research raised shares of HB Fuller from a sell rating to a hold rating in a report on Tuesday, June 11th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $202.46.
SYK opened at $210.45 on Monday. Stryker has a twelve month low of $144.75 and a twelve month high of $210.85. The business’s 50-day moving average price is $200.13. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.12 and a quick ratio of 1.30. The company has a market capitalization of $77.59 billion, a PE ratio of 28.79, a price-to-earnings-growth ratio of 2.49 and a beta of 0.87.
Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.68 earnings per share. Sell-side analysts anticipate that Stryker will post 8.15 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Thursday, June 27th. Stryker’s dividend payout ratio is currently 28.45%.
In other news, VP Bijoy Sagar sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $190.43, for a total value of $380,860.00. Following the completion of the transaction, the vice president now owns 3,350 shares of the company’s stock, valued at $637,940.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $188.21, for a total value of $508,167.00. Following the completion of the transaction, the chief financial officer now directly owns 23,333 shares of the company’s stock, valued at approximately $4,391,503.93. The disclosure for this sale can be found here. Insiders sold 21,377 shares of company stock valued at $4,144,870 in the last ninety days. 7.20% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Welch Group LLC grew its position in shares of Stryker by 1.5% during the 1st quarter. Welch Group LLC now owns 3,774 shares of the medical technology company’s stock worth $745,000 after buying an additional 54 shares during the period. Independence Bank of Kentucky grew its position in shares of Stryker by 4.9% during the 1st quarter. Independence Bank of Kentucky now owns 1,180 shares of the medical technology company’s stock worth $233,000 after buying an additional 55 shares during the period. Benedict Financial Advisors Inc. grew its position in shares of Stryker by 1.1% during the 1st quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock worth $1,034,000 after buying an additional 57 shares during the period. Berman Capital Advisors LLC grew its position in shares of Stryker by 11.1% during the 1st quarter. Berman Capital Advisors LLC now owns 571 shares of the medical technology company’s stock worth $112,000 after buying an additional 57 shares during the period. Finally, 1ST Source Bank grew its position in shares of Stryker by 3.5% during the 1st quarter. 1ST Source Bank now owns 1,760 shares of the medical technology company’s stock worth $348,000 after buying an additional 60 shares during the period. 73.57% of the stock is owned by institutional investors and hedge funds.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Commodities
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.